Frontiers of Medicine
>> 2020,
Volume 14,
Issue 6
doi:
10.1007/s11684-020-0740-6
COMMENTARY
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
. Department of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, China.. Department of Imaging, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, China.. Clinical Translational Research Center, Shanghai Pulmonary Hospital of Tongji University School of Medicine, Shanghai 200433, China
Received: 2020-04-02
Accepted: 2020-07-13
Available online: 2020-07-13
Next
Previous
Abstract
Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis. Several agents, such as proteasome inhibitors, immunomodulatory drugs, and inhibitors of B cell lymphoma-2 and Bruton’s tyrosine kinase have shown efficacy for relapsed or refractory (r/r) MCL but often have short-term responses. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin’s lymphoma. However, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especially in MCL. In this report, we described a 70-year-old patient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cell therapy. CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient. This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL, who are generally elderly and have comorbid conditions.
京公网安备 11010502051620号
